NeuroFerro · Ferroptosis Inhibitors For Neurodegenerative Disorders

Ferroptosis Inhibitors For Neurodegenerative Disorders

Neurodegenerative diseases represent a growing healthcare burden worldwide, yet there are no available cures. Recent studies have identified ferroptosis, a form of regulated cell death associated with iron and lipid peroxidation, as a significant contributor to neurodegeneration. However, effective therapeutic strategies targeting ferroptosis are lacking, especially those capable of crossing the blood-brain barrier (BBB). The NeuroFerro project aimed to address this unmet need by developing novel ferroptosis inhibitors with optimized properties for central nervous system (CNS) targeting. The primary objective was to create radical-trapping antioxidants (RTAs) with improved oral bioavailability and BBB permeability. These compounds were intended to serve both as research tools to study the role of ferroptosis in neurodegeneration and as lead candidates for drug development. Through a comprehensive research and development strategy combining medicinal chemistry, in vitro and in vivo biological evaluations, and physicochemical profiling, the project has significantly expanded the available toolbox for ferroptosis research. The outcomes contribute to Europe's efforts to advance health innovation, promote healthy ageing, and position the EU as a leader in biomedical sciences.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз